NORTH CHICAGO, Ill., July 17, 2026
Allergan Aesthetics, an AbbVie company, announced that the European Commission has approved Boey® (trenibotulinumtoxinE) for the temporary improvement of moderate to severe glabellar lines (frown lines) in adult patients when these lines have a significant psychological impact. The approval makes Boey® the first and only rapid-onset, short-duration botulinum neurotoxin serotype E approved in Europe, offering patients a differentiated facial injectable option with results that may appear as early as eight hours after treatment and typically wear off within two to three weeks. Following completion of the centralized regulatory procedure, the approval applies across all 30 European Economic Area (EEA) countries. The milestone follows Health Canada approval received earlier in June 2026, further expanding the international availability of this first-in-class aesthetic injectable. Allergan Aesthetics is preparing to launch Boey® across Europe while providing physician education and training to support its clinical use.
Rapid-Onset Neurotoxin Offers Flexible Aesthetic Treatment Option
Boey® (trenibotulinumtoxinE) introduces a new treatment option for patients seeking facial aesthetic procedures with a shorter commitment than conventional botulinum toxin products. The injectable targets SNAP-25, enabling rapid uptake into nerve cells and a shorter duration of action due to the brief half-life of the botulinum toxin type E light chain. Clinical studies demonstrated that treatment effects could begin within eight hours, reaching peak effectiveness by Day 7, before gradually returning to baseline over approximately two to three weeks. This shorter treatment duration may appeal to individuals who are interested in experiencing facial injectables before committing to longer-lasting aesthetic procedures. Company survey data also indicated growing consumer interest in more flexible aesthetic treatments, with many respondents expressing interest in temporarily previewing cosmetic outcomes before choosing longer-duration options.
Phase 3 Studies Demonstrated Efficacy and Favorable Safety Profile
The European Commission approval was supported by results from two randomized, multicenter, double-blind, placebo-controlled Phase 3 clinical trials (M21-500 and M21-508) involving 725 adult patients with moderate to severe glabellar lines. Both studies evaluated Boey® 700 units compared with placebo using investigator and patient assessments based on the 4-point Facial Wrinkle Scale. The trials met their co-primary efficacy endpoints by demonstrating significant improvements in wrinkle severity at maximum frown by Day 7. Secondary assessments also evaluated patient satisfaction with achieving a natural appearance and overall treatment outcomes. The most commonly reported adverse reactions were eyelid ptosis, brow ptosis, and Mephisto sign, each occurring at very low frequencies. Importantly, BOTOX® Cosmetic remains the only botulinum toxin clinically evaluated for safety following treatment with Boey®, providing additional clinical evidence supporting sequential treatment strategies.
Advertisement
Approval Strengthens Allergan Aesthetics’ Injectable Portfolio
The approval of Boey® further expands Allergan Aesthetics’ leadership in the global medical aesthetics market by adding a first-in-class botulinum neurotoxin type E to its established injectable portfolio. Developed by the makers of BOTOX Cosmetic®, the new product provides healthcare professionals with an additional option for patients seeking rapid-onset facial wrinkle treatment with a shorter duration of effect. According to the company, the approval reflects its continued investment in aesthetic research and development aimed at addressing evolving patient preferences through innovative technologies. With preparations underway for commercial launch across Europe, Boey® is expected to strengthen Allergan Aesthetics’ position in injectable aesthetics while expanding treatment choices for adults seeking temporary improvement of glabellar lines through scientifically validated cosmetic procedures.
Source:Allergan Aesthetics press release
